Weight loss becomes measurable, typically 24 pounds, as calorie intake naturally decreases
This analysis uses 2023 Medicare claims for traditional Medicare, Medicare Advantage encounter data, and Part D prescription drug event data to estimate the total number of Medicare beneficiaries with obesity or overweight, the number of Part D enrollees who met the Bridge eligibility criteria in 2023, and those who met the Bridge clinical criteria but who also had diagnoses recorded in claims or encounter data that would qualify for Part D coverage of GLP-1s (type 2 diabetes, OSA, or MASH) or who had a GLP-1 Part D-covered prescription during the year, either of which would make them ineligible for Bridge (see Methods)
This initial assessment allows us to customize your semaglutide dosage and set the benchmark for tracking your progress
Always read retinol with CRP (or AGP) and never ignore clinical signs such as night blindness, xerosis and Bitots spots
Additionally, an optional 52-week open-label extension was available for women who completed the core study